Analysts/Institutional Investor Meet/Con. Call Updates

August 5, 2026 To, To, National Stock Exchange of India Limited, BSE Limited, “Exchange Plaza”, Corporate Relationship Department, 5th Floor, Plot No. C/1, G Block, 2nd Floor, New Trading Ring, Bandra- Kurla Complex, Bandra (East), P.J. Towers, Dalal Street, Mumbai – 400 051 Mumbai – 400 001 Scrip Name: GLENMARK Scrip Code: 532296 ISIN: INE935A01035 ISIN: INE935A01035 Our Reference No. 41/26-27 Our Reference No. 41/26-27 Dear Sir/ Madam, Sub: Transcript of the Earnings Call Further to our letter dated July 21, 2026 and pursuant to Regulation 30(6) read with Part A of Schedule III of SEBI (LODR), Regulations 2015, the transcript of the Earnings call held on Monday, August 03, 2026 for the quarter ended June 30, 2026 has been uploaded on the Company’s website at https://glenmark.b-cdn.net/gpl_pdfs/Financials/Quarterly/Glenmark-Earnings-Aug03-2026- Revised.pdf Request you to kindly take the same on record. Thanking you. Yours faithfully, For Glenmark Pharmaceuticals Limited Rashmi Khandelwal Company Secretary & Compliance Officer ACS - 28839 Glenmark Pharmaceuticals Limited Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099 T: 91 22 4018 9999 F: 91 22 4018 9988 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com